← Back to Search

Mesenchymal Stromal Cells

Allogeneic Wharton's jelly-MSCs (WJ-MSC) for Coronavirus (ProTrans19+ Trial)

Phase 2
Waitlist Available
Led By Ines Colmegna
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 7, 15 and 30
Awards & highlights

ProTrans19+ Trial Summary

This trial tests if a treatment using stem cells can help treat COVID, alongside standard care.

Eligible Conditions
  • Coronavirus

ProTrans19+ Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from enrolment to discharge or icu transfer or death
This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrolment to discharge or icu transfer or death for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Composite endpoint
Secondary outcome measures
Clinical status evaluation assessed by the 9-point ordinal scale
Duration of hospitalization and ICU stay
Survival
+1 more

ProTrans19+ Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Allogeneic Wharton's jelly-MSCs (WJ-MSC)Experimental Treatment1 Intervention
Intravenous administration, 1 dose, for 20 minutes
Group II: PlaceboPlacebo Group1 Intervention
Intravenous administration, 1 dose, for 20 minutes

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
450 Previous Clinical Trials
159,827 Total Patients Enrolled
Ines ColmegnaPrincipal InvestigatorResearch Institute of the McGill University Health Centre
~5 spots leftby Jun 2025